In a sea of rising tides within the Pharmaceuticals industry during the week of June 1, 2023, to June 8, 2023, Bausch Health Companies (BHC, $7.1) found itself in a downward current. The company's share prices fell by a notable 13.41%, landing it on the list of the week's top losers. This decline contrasts with the overall industry trend, where 218 out of 312 analyzed stocks, or an impressive 69.77%, showed an uptrend.
Bausch Health Companies, a renowned player in the Pharmaceuticals industry, has been navigating through a challenging period. The substantial drop in its share prices underscores the complex dynamics that companies like Bausch Health are dealing with, including potential regulatory changes, market competition, and the impacts of global health crises.
Experience the next level of trading intelligence with Tickeron's AI robots, revolutionizing decision-making strategies.
At the same time, the Pharmaceuticals industry witnessed robust growth. Of the 312 stocks tracked during the week, 218 registered an uptrend, indicating strong market sentiment and substantial growth for nearly 70% of the sector. Nevertheless, 94 stocks, comprising 30.23% of the sector, experienced a downtrend, with Bausch Health Companies featuring prominently in this category.
The stark contrast between the upward trajectory of the majority of pharmaceutical companies and the decline experienced by Bausch Health Companies reflects the dynamic and often unpredictable nature of the pharmaceutical market. Multiple factors, from drug development pipelines and regulatory approval processes to global health trends and market competition, can influence a company's performance.
While Bausch Health's downturn represents a rough patch, it's crucial to remember that the financial landscape is ever-evolving. Today's top losers can be tomorrow's winners. As we continue monitoring the trends in the Pharmaceuticals industry and the performance of Bausch Health Companies, our commitment remains to provide you with the most relevant and timely market updates. Keep following for more insights and always approach investment decisions with caution and informed judgment.
The 10-day RSI Oscillator for BHC moved out of overbought territory on October 07, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on October 18, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BHC as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BHC turned negative on October 07, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BHC broke above its upper Bollinger Band on September 16, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The 10-day moving average for BHC crossed bullishly above the 50-day moving average on September 16, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BHC advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 159 cases where BHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (56.029). P/E Ratio (13.387) is within average values for comparable stocks, (89.935). BHC's Projected Growth (PEG Ratio) (0.011) is slightly lower than the industry average of (2.890). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.433) is also within normal values, averaging (18.706).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry PharmaceuticalsOther